RavenQuest completes first cannabis shipment to Wayland Group

RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest” – https://www.commodity-tv.net/c/search_adv/?v=298814 ) a federally licensed producer of cannabis, is pleased to announce it has completed its first shipment of bulk cannabis to Wayland Group.

The shipment was made as part of a larger agreement between RavenQuest and Wayland group, whereby RavenQuest will supply up to 8,000 kg of bulk cannabis to Wayland Group. The agreement spans the entirety of calendar 2019.

CEO, George Robinson commented that “it has been a pleasure dealing with Ben Ward and the entire team at Wayland Group. We are very excited to complete this first shipment, which represents the beginning of our agreement as we fulfill our commitment to supply premium cannabis to our partners at Wayland.”

“The new license at our Edmonton facility brings significantly more capacity onstream, dramatically increasing our revenue potential for 2019. In addition to this agreement, we have also signed an MOU to supply cannabis to the British Columbia Liquor Distribution Branch. Between these two distribution channels and based upon prevailing B2B market prices, we’re confident we can ramp up revenue to north of the budgeted $44.5 million for 2019.” Robinson continued.

For more information, view RavenQuest’s updated website at www.rqbglobal.com.

Follow RavenQuest on Twitter @RQBGlobal

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of AVENQUEST BIOMED INC.

"George Robinson" Chief Executive Officer

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to anticipated production capacity. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Readers are cautioned that budgeted revenue is based upon prevailing prices for the supply of cannabis products in business-to-business transactions, and assumes annual production of 11,000 kilograms of cannabis from the Company’s Edmonton facility. A number of factors may cause actual results to differ materially from budgeted amounts, including changes in the market price and demand for cannabis products, interruptions in production and operations at the Company’s facility and an evolving government and regulatory landscape.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

RavenQuest Provides Update on Recent License and Production Capacity Expansion

RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest” – https://www.commodity-tv.net/c/search_adv/?v=298814 ) a federally licensed producer of cannabis, is pleased to provide an update following receipt of its cultivation license at its Edmonton facility and the capacity expansion that comes with it.

Licensing of the Edmonton facility represents an inflection point for the Company, increasing its licensed annual cannabis production capacity to 11,000 kg—a 275% increase.

RavenQuest currently has a supply agreement with Wayland Group, whereby RavenQuest has agreed to supply them with up to 8,000 kg of cannabis in 2019.  RavenQuest has also entered a memorandum of understanding with the British Columbia Liquor Distribution Branch (“BCLDB”) and expects to enter into an agreement in to sell the remainder of its cannabis production to them in 2019.

With respect to ramping up production at the newly licensed Edmonton facility, RavenQuest CEO, George Robinson stated “we have an experienced team in place at both Edmonton and Markham facilities to ensure starting material is expedited safely from the Markham facility to the Edmonton facility.  Our experience in cannabis consulting, together with the seasoned plant expertise of Dr. Simerjeet Kaur and her team will enable us to bring production online in Edmonton properly and at a rapid pace”.

“With the Edmonton facility online, RavenQuest is on track to fulfill its supply agreement with the Wayland Group and expects to be in a position to supply the BCLDB with cannabis once a definitive supply agreement is reached” Robinson continued.

In addition to an increase in cannabis revenue for 2019, RavenQuest also anticipates a record year for its Services Division, with several new clients signing contracts including, notably, a one year agreement with Bonify valued at $1.5 million.

Once legalized, RavenQuest intends to deliver on its broader growth strategy to provide value-added products across a wide spectrum of delivery options including vaporization, edibles and beverages.  “Our plans include a diversified product offering of unique experiences for cannabis consumers.  These products will differ substantially from the fractional distillates planned by our competitors.  Instead, we will place the emphasis on the full plant extract, with the myriad flavours and profiles that come with passing through the full plant experience to value added products” stated Robinson.

“As we move past the licensing phase,” stated Robinson, “2019 promises to be an unprecedented year for RavenQuest and our stakeholders.  We are excited to take the Company from the buildout phase to the revenue and profitability phase, and continuing to accelerate our growth trajectory.  There is much to look forward to for RavenQuest BioMed in 2019.”

For more information, view RavenQuest’s updated website at www.rqbglobal.com.

The BCLDB is responsible for regulating private retail cannabis licensing and the distribution of cannabis to retail stores in British Columbia’s legal adult-use recreational cannabis marketplace. The MOU does not represent a binding purchase agreement, and any distribution of cannabis products to the BCLDB is subject to the negotiation of such an agreement on the terms specified by the BCLDB. The Company will provide additional information regarding the BCLDB supply and distribution process as it becomes available.

Follow RavenQuest on Twitter @RQBGlobal

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.  RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant.  The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

"George Robinson"
Chief Executive Officer

For further information, please contact: Mathieu McDonald, Corporate Communications
1-877-282-1586

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to anticipated production capacity.  The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes.  By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved.  These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements.  The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Ravenquest Secures Health Canada Cultivation License at Edmonton Facility

RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest” – https://www.commodity-tv.net/c/search_adv/?v=298814) a federally-licensed producer of cannabis, is pleased to announce it has secured a Health Canada License to Cultivate at the Company’s flagship Edmonton facility.  The license allows RavenQuest to begin cannabis production inside the revolutionary Orbital Garden 2.0 grow technology at its ultra-modern Edmonton production facility.  The Edmonton facility increases RavenQuest’s production capacity by 275%, adding 7,000 kg of annual capacity and bringing the Company’s total production capacity to approximately 11,000 kg per year.

George Robinson, CEO of RavenQuest, stated “this is a very exciting time and inflection point for our organization.  This milestone catapults our company toward dramatic cannabis production and revenue increases for 2019.   We have been busy preparing for this pivotal moment.  Our Edmonton team is ready and all equipment is in place, including our Orbital Garden 2.0 technology.  Starting material has been carefully prepared and curated at our Markham facility and will be moved to Edmonton to begin production immediately” Robinson continued.

“Production will be ramped up rapidly and efficiently in order to meet supply agreements with our provincial partner, BCLDB, as well as major bulk buyer, Wayland Group” stated Robinson.  “We have already pre-sold all cannabis production from our Markham and Edmonton facilities for the calendar year of 2019” he continued.

For more information, access RavenQuest’s investor presentation, fact sheet and videos here.

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.  RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant.  The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

"George Robinson"
Chief Executive Officer

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to anticipated production capacity.  The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes.  By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved.  These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements.  The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Sibanye-Stillwater releases its Annual suite of reports, the AGM Notice and the No Change Report

Sibanye-Stillwater (Tickers JSE: SGL and NYSE: SBGL – https://www.commodity-tv.net/c/search_adv/?v=298805) is pleased to advise that its 2018 Integrated Annual Report, Annual Financial Report, Company Financial Statements, Summarised Report, the Notice of Annual General Meeting and the Mineral Resources and Mineral Reserves supplement as well as other relevant supplementary documentation, have been released on its website at http://reports.sibanyestillwater.com/….

The Summarised Report including the Notice of the AGM to shareholders will be posted today.

The Group’s auditors KPMG Inc., has audited the 2018 consolidated and company financial statements and its unqualified audit report is open for inspection at the Company’s offices. The information previously published in the preliminary results released on 21 February 2019 has not changed.

Notice of Annual General Meeting

The Annual General Meeting of the Company (AGM) for the year ended 31 December 2018 will be held at the South African Operations’ Academy, Rietkloof 349, Glenharvie, 1786, South Africa, on 28 May 2019 at 09:00 (CAT). The AGM will conduct the business as stated in the notice of the meeting, a copy of which can be found on https://www.sibanyestillwater.com/….  

In terms of section 59(1) (b) of the Companies Act, 71 of 2008, the record date for the purpose of determining which shareholders are entitled to participate in and vote at the AGM (being the date on which a shareholder must be registered in the Company’s securities register in order to participate in and vote at the AGM) is Monday, 27 May 2019 (not Sunday, 26 May 2019 as incorrectly stated in the printed notice of meeting). The last day to trade in order to be registered in the Company’s securities register is Wednesday, 22 May 2019.

FORWARD LOOKING STATEMENTS

This announcement includes “forward-looking statements” within the meaning of the “safe harbour” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target”, “will”, “forecast”, “expect”, “potential”, “intend”, “estimate”, “anticipate”, “can” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. The forward-looking statements set out in this announcement involve a number of known and unknown risks, uncertainties and other factors, many of which are difficult to predict and generally beyond the control of Sibanye-Stillwater, that could cause Sibanye-Stillwater’s actual results and outcomes to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this announcement. Sibanye-Stillwater undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, save as required by applicable law.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Meyer Burger acquires 18.4% of Oxford PV and issues 62,288,420 registered shares out of the existing authorised capital

Meyer Burger Technology Ltd (SIX Swiss Exchange: MBTN) reported today the successful acquisition of a major equity stake in Oxford Photovoltaics Limited (Oxford PV), as announced on 21 March 2019. Simultaneously with the placement of Meyer Burger Technology Ltd shares by way of an accelerated bookbuilding procedure conducted by Oxford PV (as announced on 27 March 2019), Meyer Burger Technology Ltd has issued 62,288,420 registered shares out of its existing authorised capital. The issuance will increase Meyer Burger’s listed share capital to CHF 34,258,691.70, divided into 685,173,834 registered shares with a nominal value of CHF 0.05 each. The listing of these shares on SIX Swiss Exchange has already been applied for by the company and was approved by SIX Swiss Exchange. With the closing of the transaction, Meyer Burger will become the largest shareholder in Oxford PV. Hans Brändle, Meyer Burger CEO, will become member of the Board of Directors of Oxford PV.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR, EXCHANGE OR PURCHASE ANY SECURITIES. IN ADDITION, THE SECURITIES OF MEYER BURGER TECHNOLOGY LTD HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS.

This press release may contain “forward-looking statements”, such as guidance, expectations, plans, intentions, or strategies regarding the future. These forward-looking statements are subject to risks and uncertainties. The reader is cautioned that actual future results may differ from those expressed in or implied by the statements, which constitute projections of possible developments. All forward-looking statements included in this press release are based on data available to Meyer Burger Technology Ltd as of the date that this press release is published. The company does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Meyer Burger – Sentis Capital PCC requests agenda items for the Annual General Meeting of 2 May 2019

Meyer Burger Technology AG (SIX Swiss Exchange: MBTN) has received a request from Sentis Capital PCC (“Sentis”) for agenda items for the Annual General Meeting of 2 May 2019. Sentis requests several changes of the Articles of Association: cancellation of the authorised capital, amendment of the percentage limit regarding shareholders’ rights to convene a general meeting, amendment of the percentage limit of shareholders’ rights to request that matters be put on the agenda and introduction of a period between the publication of the annual report and the date of the Annual General Meeting, change of the number of permitted mandates outside Meyer Burger Group as well as the introduction of a maximum number of years that the statutory auditors can be mandated.

 

The Board of Directors will examine these requests and will comment on it in due course.

 

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR, EXCHANGE OR PURCHASE ANY SECURITIES. IN ADDITION, THE SECURITIES OF MEYER BURGER TECHNOLOGY LTD HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS.

 

This press release may contain “forward-looking statements”, such as guidance, expectations, plans, intentions, or strategies regarding the future. These forward-looking statements are subject to risks and uncertainties. The reader is cautioned that actual future results may differ from those expressed in or implied by the statements, which constitute projections of possible developments. All forward-looking statements included in this press release are based on data available to Meyer Burger Technology Ltd as of the date that this press release is published. The company does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Directorate changes

In terms of Section 3.59 of the Listings Requirements of the JSE Limited, Sibanye-Stillwater announces the resignation and retirement of Barry Davison as an Independent Non-Executive Director of the Company at the upcoming Annual General Meeting scheduled for 28 May 2019.

Barry has been an integral part of the Sibanye-Stillwater Board since the Company’s inception in 2013 and has served as Chairman of the Company’s Health and Safety Committee since then. Harry Kenyon-Slaney who has vast experience in health, safety and business transformation programmes will in future Chair the committee.

The Board extends its profound appreciation to Barry for his invaluable contribution to the Group and sage advice over the last six years.

FORWARD LOOKING STATEMENTS

This announcement includes “forward-looking statements” within the meaning of the “safe harbour” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target”, “will”, “forecast”, “expect”, “potential”, “intend”, “estimate”, “anticipate”, “can” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. The forward-looking statements set out in this announcement involve a number of known and unknown risks, uncertainties and other factors, many of which are difficult to predict and generally beyond the control of Sibanye-Stillwater, that could cause Sibanye-Stillwater’s actual results and outcomes to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this announcement. Sibanye-Stillwater undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, save as required by applicable law.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

World Energy Day on October 22: Is Germany the European energy-saving champion?

Is Germany the European energy-saving champion? According to a survey by E.ON and KantarEMNID, at least 14 percent of Germans believe so, but the reality is rather different. Of the ten European countries covered in the survey, Romania takes first place with a primary energy consumption of 18,515 kilowatt hours (kWh) per head each year.

Second and third places go to Turkey and Hungary, with an annual consumption of 19,271 and 28,296 kWh, respectively. Those questioned in the survey believed – entirely incorrectly – that these places would go to Denmark (16 percent) and Germany (11 percent).

They also placed Hungary – which in reality comes in third – in last place with just one percent. Only two percent of those surveyed thought that Romania, which actually uses the least energy, was Europe’s energy-saving champion.

All those questioned believed the title should go to a nation in the north of the continent. On average, across all the countries in the survey, 26 percent believe Sweden is the best at saving energy, hence it was placed top in nine out of ten countries among those questioned by E.ON and KantarEMNID – who were therefore entirely wrong. Incidentally, the Danes are the only ones to be firmly convinced – likewise incorrectly – that their own nation takes the title, with a total of 34 percent.

These results are part of the “Living in Europe” study, for which E.ON and KantarEMNID questioned around 10,000 people in the Czech Republic, Denmark, France, Germany, Hungary, Italy, Romania, Sweden, Turkey and the UK. The energy consumption figures are based on the World Bank’s World Development Indicators (2015), published by the Federal Statistical Office.

This press release may contain forward-looking statements based on current assumptions and forecasts made by E.ON Group Management and other information currently available to E.ON. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. E.ON SE does not intend, and does not assume any liability whatsoever, to update these forward-looking statements or to align them to future events or developments.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Barlow Robbins Solicitors, Ecovis’ UK legal partner, recruits life sciences partner

The UK has one of the largest life sciences markets in the world and the sector commands an important position within the UK economy.

Barlow Robbins has recruited Tim Matthews as an additional partner in its Corporate and Commercial group. Tim has wide experience in the life sciences sector with over 25 years’ experience acting for UK-listed international and private companies primarily from the life science and technology sectors.

Life sciences sector clients require specialist advice on a wide range of legal areas such as creating commercial agreements for product manufacturing and research, or for advice on navigating the many regulatory issues in this sector. The expertise also extends to brand protection with strategic advice on copyright laws and intellectual property rights.

Due to the sheer size of this industry the needs of our client base are going to become more international. We are perfectly placed to meet these needs and look forward to supporting our clients as they adapt to a changing environment, in co-operation with our other colleagues throughout the global Ecovis network.

Barlow Robbins life sciences work highlights

  • Tim Matthews previously advised Midatech Pharma PLC, an international pharmaceutical company, on its acquisition of DARA BioSciences, a NASDAQ-listed oncology supportive care pharmaceutical company based in North Carolina.
  • Supporting family owned Veriton Pharma formerly Special Products, on their product portfolio, export network and product licensing. Mark Lucas comments, “Supporting an SME that has ambitious plans to grow globally is exciting, and perfectly aligned to our business. They have a good appetite for risk and genuinely appreciate our expertise and advice. It has been great to see the evolution of their balanced portfolio of projects in an equally balanced portfolio of territories, growing into Dubai to service the Middle East territories; and in Melbourne, Australia – all with the plan of mitigating risks after BREXIT!”

Author

Tim Matthews, Partner in the Corporate and Commercial Department, Barlow Robbins LLP, Guildford, Surrey, UK

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Elanix Biotechnologies AG announces cash capital increase with indirect subscription rights from currently EUR 7,779,139 by up to EUR 777,910 to up to EUR 8,557,049

.

– Subscription period for current shareholders from July 27 to August 10, 2018 

– Subscription price for shareholders to be EUR 2.75

– Management explaining planned usage of capital raised and future milestones

Elanix Biotechnologies AG ("Elanix"; "Company"), a developer of tissue regeneration products and Advanced Skin Care in the field of dermatology and gynaecology, has announced a cash capital increase via an ad-hoc news today. According to the Management the capital increase will be used to strengthen the business activities by enlarging the product portfolio, by enlarging the distribution and sales network, by running a dynamic e-commerce campaign of the Elanix Advanced Care products, and by further investments in the development and industrialization of the Advanced Wound Care products.

Tomas Svoboda explaining: "Some milestones have already been achieved in the first half of 2018, including the passing of agreements with distribution partners and key accounts in Germany, France, Switzerland and Russia, the strengthening of the management team with an experienced COO&CFO and a Business Head for Advanced Skin Care, and the development of a new e-commerce website. The market launch of SKINrepair will take place during Q4 2018."

The capital increase will be legally designed in such a way that it does not require a securities prospectus under German law pursuant to §§ 3 (2) no. 5, 4 (2) German Prospectus Act ("WpPG") in the new version as of 21 July 2018. During the subscription period from (expected) 27 July to 10 August, shareholders may exercise their subscription rights (ISIN DE000A2G9KU4) by way of their depository bank and can subscribe to new shares of the Company at a ratio of 10:1 (ten existing shares allow a subscription of one new share) at a price of EUR 2.75 per new share. The subscription price is based on the average closing share price of the last five trading days at Frankfurt Stock Exchange before fixing the final issued share price minus 10% subscription discount.

In addition, shareholders can register for so-called supplement subscriptions ("over-subscription") through their depository bank but will not automatically be guaranteed an allotment of shares. Any shares not purchased in the course of the pre-emptive rights offering will be offered to selected investors in the form of a private placement. The share price for the private placement will be, at minimum, the offered share price during the subscription period. Totally up to 777,910 new shares might be issued through this cash capital increase. The subscription rights offer will be available on the company website at https://elanixbiotechnologies.com/… under Capital Increase in the Investor Relations section and also at Federal Gazette ("Bundesanzeiger") from expected July 27 on.

Disclaimer

This publication may not be published, distributed or transmitted, directly or indirectly, in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction where such an announcement could be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons who are in possession of this document or other information referred to herein should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This publication does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of Elanix Biotechnologies AG in the United States of America, Germany or any other juris-diction. In connection with this transaction there will be no publication of a securities prospectus.

Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. The securities referred to herein may not be offered or sold in the United States of America in the absence of registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The securities of Elanix Biotechnologies AG have not been, and will not be, registered under the Securities Act.

This announcement does not constitute a recommendation concerning the placement of securities described in this announcement. Investors should consult a professional advisor as to the suitability of the Placement for the person concerned.

In the United Kingdom, this document is only directed at persons who (i)are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.)(all such persons together being referred to as "Relevant Persons"). This document must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

In member states of the European Economic Area which have implemented the Prospectus Directive (each, a "Relevant Member State"), this announcement and any offer, if made subsequently, is directed exclusively at persons who are "qualified investors" within the meaning of the Prospectus Directive. For these purposes, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State.

No action has been taken that would permit an offering of the securities, a purchase of the securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.

This announcement also does not constitute a prospectus within the meaning of the EU Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003 as amended ("Prospectus Directive").

Forward-looking statements

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

The information contained in this release is NOT to be published OR forwarded in or into the United States of America, Australia, Canada or any other country where such a distribution or publication could be unlawful.

 

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox